Lipoprotein Apheresis in the Treatment of Dyslipidemia – the Czech Republic Experience
Authors:
- V. BláhaVBV. Bláha
- M. BláhaMBM. Bláha
- M. LánskáMLM. Lánská
- D. SolichováDSD. Solichová
- L. Kujovská KrčmováLKL. Kujovská Krčmová
- E. HavelEHE. Havel
- P. VyroubalPVP. Vyroubal
- Z. ZadákZZZ. Zadák
- P. ŽákPŽP. Žák
- L. SobotkaLSL. Sobotka
- 15 April 2017
- journal article
- Published by Institute of Physiology of the Czech Academy of Sciences in Physiological Research
- Vol. 66, S91-S100
Abstract
In 1984, we started using therapeutic plasmapheresis (plasma exchange) as a method of extracorporeal lipoprotein elimination for the treatment of hypercholesterolemic patients. We evaluated the results of long-term therapy in 14 patients, 8 men and 6 women. The average age was 55.6±13.2 (range 28-70), median 59.5 years. 14 patients were diagnosed with familial hypercholesterolemia (FH): 5 homozygous, 9 heterozygous. Ten patients in the group were treated using immunoadsorption lipoprotein apheresis and 4 using hemorheopheresis. Immunoapheretic interventions decreased LDL-cholesterol (82±1 %), ApoB (73±13 %) and even Lp(a) by 82±19 %, respectively. Selected non-invasive methods are important for long-term and repeated follow-up. Carotid intima-media thickness showed improvement or stagnation in 75 % of the patients. Biomarkers of endothelial dysfunction such as endoglin (in the control group: 3.85±1.25 μg/l, in lipoprotein apheresis-treated hypercholesterolemic individuals 5.74±1.47 μg/l), CD40 ligand (before lipoprotein apheresis: 6498±2529 ng/l, after lipoprotein apheresis: 4057±2560 ng/l) and neopterin (before lipoprotein apheresis: 5.7±1.1 nmol/l, after lipoprotein apheresis: 5.5±1.3 nmol/l) related to the course of atherosclerosis, but did not reflect the actual activity of the disease nor facilitate the prediction or planning of therapy. Hemorheopheresis may improve blood flow in microcirculation in familial hypercholesterolemia and also in some other microcirculation disorders via significantly decreased activity of thrombomodulin (p<0.0001), tissue factor (p<0.0001), aggregation of thrombocytes (p<0.0001) and plasma and whole blood viscosity (p<0.0001). In conclusion, lipoprotein apheresis and hemorheopheresis substantially lowered LDL-cholesterol in severe hypercholesterolemia. Our experience with long-term therapy also shows good tolerance and a small number of complications (6.26 % non-serious clinical complications).Keywords
This publication has 34 references indexed in Scilit:
- Single Low-Density Lipoprotein Apheresis Does Not Improve Vascular Endothelial Function in Chronically Treated Hypercholesterolemic PatientsInternational Journal of Vascular Medicine, 2016
- The decrease of mean platelet volume after extracorporeal LDL-cholesterol eliminationAtherosclerosis Supplements, 2013
- Extracorporeal LDL cholesterol elimination (25 years of experience in CZ)Atherosclerosis Supplements, 2009
- CHANGES OF LABORATORY PARAMETERS DURING LONG-TERM EXTRACORPOREAL LDL-CHOLESTEROL ELIMINATIONAtherosclerosis Supplements, 2008
- Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemiaAtherosclerosis, 2007
- Safety and Tolerability of Long Lasting LDL‐apheresis in Familial HyperlipoproteinemiaTherapeutic Apheresis and Dialysis, 2007
- Activity of thrombocytes as a marker of sufficient intensity of LDL-apheresis in familial hypercholesterolaemiaTransfusion and Apheresis Science, 2004
- Low‐density Lipoprotein Apheresis: An OverviewTherapeutic Apheresis and Dialysis, 2003
- Extracorporeal LDL-Cholesterol Elimination in the Treatment of Severe Familial HypercholesterolemiaActa Medica (Hradec Kralove, Czech Republic), 2003
- Acute and long-term effects of low-density lipoprotein apheresis on the serum concentrations of vitamins E and AJournal of Molecular Medicine, 1988